Theravance Biopharma announced a sweeping restructuring after its norepinephrine reuptake inhibitor ampreloxetine failed a Phase III study in multiple system atrophy and symptomatic neurogenic orthostatic hypotension. The company will wind down its R&D organization and cut its workforce roughly in half while refocusing on its approved respiratory product. Management said the Phase III program missed its primary endpoint, prompting an end to development of ampreloxetine and an immediate strategic pivot to stabilize cash burn and preserve core commercial operations. The move follows prior late‑stage setbacks for the asset and underscores the high binary risk of pivotal trials for single‑asset biotechs; Theravance plans to generate cash flow from existing marketed medicines while exploring strategic alternatives for the company. For biotech operators and deal teams: the filing highlights how a single pivotal failure can force immediate portfolio contraction and creates potential M&A, asset sale or licensing opportunities for remaining programs and capabilities.